Home :: Scrip
Error! The "meta description" is missing, the page has no summary description!
- Make the site mobile device friendly.
- Select one version of your site as main and make a redirect from other versions to that one.
- Avoid using deprecated HTML tags.
Domain : scrip.pharmamedtechbi.com/
Character length : 26
Good! The OG (Open Graph) protocol is set on this website.
url: https://scrip.pharmamedtechbi.com/
type: website
site_name: Scrip
image: scrip.pharmamedtechbi.com/-/media/editorial/stock-images/business-chart-with-glowing-arrows-and-world-map.jpg
title: Scrip :: Informa Pharma Intelligence
description: A real-time digital news and analysis information service first published more than 40 years ago, Scrip now serves the global pharmaceutical industry. Headed up by 20 leading editors in key territories including Europe and Asia, Scrip is the leading digital source of news, intelligence and strategic analysis. Improve your business’ decision-making and keep abreast the latest hot topics with real-time digital intelligence and objective insights.
https://scrip.pharmamedtechbi.com/robots.txt
User-agent | Disallowed for the search engines |
---|---|
MJ12bot |
|
Linkedin86
Facebook Share0
Facebook Comments0
Character length : 13
Good! The title’s length is between 10 and 70 characters.
Acceptable! The text / code ratio is between 15 and 25 percent.
H1 | H2 | H3 | H4 | H5 | H6 |
---|---|---|---|---|---|
19 | 0 | 15 | 2 | 0 | 20 |
- <H6> Analysis
- <H1> Novartis Claims New Drugs, Pipeline Will Fuel Growth, Not M&A
- <H6> Analysis
- <H1> Biogen Staying "Laser-Focused" On Neuroscience
- <H6> Analysis
- <H1> 1Q Pharma Results Preview: Biogen, Novartis, Lilly, Amgen, GSK, AstraZeneca, BMS, AbbVie, Roche, Bayer, Sanofi
- <H6> Analysis
- <H1> Lilly Shows Diabetes Dominance, But Will It Last?
- <H3> Get Our Free Email Newsletter
- <H3> Get Our Free Email Newsletter
- <H3> Get Our Free Email Newsletter
- <H1> Commercial Explore this Topic
- <H6> News
- <H3> Fresenius Covers All Bases With Akorn Acquisition And Merck Biosimilar Buy
- <H6> Analysis
- <H3> Discounts Will Be Key Factor In US Uptake Of Samsung's Renflexis
- <H4> Latest From Commercial
- <H6> News
- <H1> Roche Faces Probe On Claims It Derailed Biosimilar Herceptin
- <H6> News
- <H1> Asia Executives To Watch: Takeda Turns To Local Talent In Changing China
- <H6> Analysis
- <H1> Can Barlow Flip E-Therapeutics From A Miss To A Hit?
- <H6> Analysis
- <H1> Deal Watch: Novartis Signs Deals In Migraine & Diabetes
- <H6> News
- <H1> Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question
- <H6> Analysis
- <H1> BioMarin Could Launch Brineura Concurrently In US And Europe
- <H1> Policy & Regulation Explore this Topic
- <H6> Analysis
- <H3> Biogen’s Spinraza Needs Long-Term Confirmatory Data, Says EMA
- <H6> News
- <H1> Pfizer Gets First Regulatory Nod For Besponsa
- <H6> Analysis
- <H1> Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
- <H6> Analysis
- <H1> India Pricing Authority Chief Says List Is No Attempt To Vilify Industry
- <H1> Research & Development Explore this Topic
- <H6> Analysis
- <H3> Stealthy NGM And Bristol Emerge As Serious NASH Competitors
- <H4> Latest From Research & Development
- <H6> News
- <H1> Celyad VP On IP Issues, Development Timelines For CAR-T Therapies
- <H6> Analysis
- <H1> Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal
- <H6> News
- <H1> Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question
- <H3> You must sign in to use this functionality.
- <H3> Forgot your password?
- <H3> Please Sign In
- <H3> Forgot your password?
- <H3> Register
- <H3> Email Article
- <H3> Sign In To Set a Search Alert
- <H3> Forgot your password?
- email25
- please22
- apr20
- bookmark20
- analysis15
- password15
- address12
- scrip11
- business10
- all9
- sign9
- development8
- sales8
- support8
- news7
- market7
- sent7
- enter7
- clinical7
- account7
- companies6
- forgot6
- policy6
- trials6
- lilly6
- pricing6
- reset6
- data6
- informa6
- novartis5
- able5
- register5
- call5
- first5
- biosimilar5
- been5
- commercial5
- regulatory5
- approvals5
- drug5
- therapy5
- unfortunately4
- products4
- valid4
- earnings4
- watch4
- diabetes4
- plc4
- get4
- research4
- pipeline4
- process4
- free4
- article4
- make4
- strategies4
- india4
- fields4
- need4
- new4
word | title | descriptions | heading |
---|---|---|---|
please | |||
apr | |||
bookmark | |||
analysis | |||
password |
- your password10
- reset your5
- clinical trials4
- email address4
- unfortunately we've4
- able to process4
- please enter a valid4
- please try again4
- unfortunately we've not4
- with your account3
- email will be sent3
- enter the email address3
Alternate attributes for the following 9 images are missing. Search engines use "alt" tags to understand image content efficiently. We strongly recommend fixing this issue.
- https://scrip.pharmamedtechbi.com/-/media/images/scrip/logo.png
- https://scrip.pharmamedtechbi.com/-/media/images/scriplogoprint.png
- https://scrip.pharmamedtechbi.com/.. /humanheadwithbrainneurons_sergeyshendero...
- https://scrip.pharmamedtechbi.com/.. /diabetesconcept_56048224_1200x675.jpg
- https://scrip.pharmamedtechbi.com/.. /emailicontwitter.png?h=18&w=20&hash=8E1E...
- https://scrip.pharmamedtechbi.com/.. /samsung_bioepis_hq_1200x675.jpg?w=784&am...
- https://scrip.pharmamedtechbi.com/.. /sc1704_thumbs_up_286007429_1200.jpg?w=78...
- https://scrip.pharmamedtechbi.com/-/media/images/emailiconrss.png
Deprecated HTML tags | Occurrences |
---|---|
<center> | 1 |
Deprecated HTML tags | Occurrences |
---|---|
<center> | 1 |
- https://scrip.pharmamedtechbi.com/dist/js/index.js
- https://scrip.pharmamedtechbi.com/dist/index-generated.css
Internal links: 100
External links: 26
External links:
Internal links:
- H3 : Get Our Free Email Newsletter, ( 0px from top )
- H3 : Get Our Free Email Newsletter, ( 0px from top )
- H3 : You must sign in to use this functionality., ( 0px from top )
- H3 : Forgot your password?, ( 0px from top )
- H3 : Please Sign In, ( 0px from top )
- H3 : Forgot your password?, ( 0px from top )
- H3 : Register, ( 0px from top )
- H3 : Email Article , ( 0px from top )
- H3 : Sign In To Set a Search Alert, ( 0px from top )
- H3 : Forgot your password?, ( 0px from top )
- H6 : Analysis, ( 502px from top )
- H6 : News, ( 502px from top )
- H1 : 1Q Pharma Results Preview: Merck, Pfizer, Gilead, Novo Nordisk, Shire, Allergan, Teva , ( 544px from top )
- H1 : BioMarin Expects 30% Markdown For Orphan Pediatric Drug Brineura , ( 544px from top )
- H6 : Analysis, ( 677px from top )
- H1 : Few Clouds On High-Priced, Ultra-Orphan Drug Horizon , ( 719px from top )
- H6 : Analysis, ( 1386px from top )
- H1 : Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q , ( 1428px from top )
- H3 : Get Our Free Email Newsletter, ( 2686px from top )
- H1 : Commercial Explore this Topic , ( 2938px from top )
- H6 : Analysis, ( 3201px from top )
- H3 : After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three , ( 3235px from top )
- H6 : Analysis, ( 3749px from top )
- H3 : BioInvent CEO On Pfizer Immunotherapy Alliance , ( 3789px from top )
- H4 : Latest From Commercial , ( 4104px from top )
- H6 : Analysis, ( 4189px from top )
- H6 : News, ( 4189px from top )
- H6 : Analysis, ( 4189px from top )
- H6 : Analysis, ( 4189px from top )
- H6 : Analysis, ( 4189px from top )
- H6 : Analysis, ( 4189px from top )
- H1 : AbbVie's Gonzalez Calls Break-Up Proposal Rational, But Premature , ( 4237px from top )
- H1 : Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline , ( 4237px from top )
- H1 : Roche Delivers Strong Quarter On Ocrevus Launch, Pipeline Promise , ( 4237px from top )
- H1 : Bayer Ups Guidance While Pharma Head Highlights NHL Drug Copanlisib , ( 4237px from top )
- H1 : Glenmark Readying Xolair Biosimilar Challenge , ( 4237px from top )
- H1 : Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance , ( 4237px from top )
- H1 : Policy & Regulation Explore this Topic , ( 4650px from top )
- H6 : News, ( 4913px from top )
- H3 : Novartis Slapped With New $49m Fine For Korea ‘Rebates’ , ( 4947px from top )
- H6 : Analysis, ( 5309px from top )
- H6 : News, ( 5309px from top )
- H6 : Analysis, ( 5309px from top )
- H1 : Biogen’s Spinraza Needs Long-Term Confirmatory Data, Says EMA , ( 5357px from top )
- H1 : Pfizer Gets First Regulatory Nod For Besponsa , ( 5357px from top )
- H1 : Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance? , ( 5357px from top )
- H1 : Research & Development Explore this Topic , ( 5770px from top )
- H6 : Analysis, ( 5928px from top )
- H3 : Hep B Cure May Lie In Reducing Surface Antigen , ( 5962px from top )
- H4 : Latest From Research & Development , ( 6299px from top )
- H6 : News, ( 6408px from top )
- H6 : News, ( 6408px from top )
- H6 : News, ( 6408px from top )
- H1 : Kiadis Aims To Boost Stem Cell Transplant Market With Adjuvant Filing , ( 6456px from top )
- H1 : Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities , ( 6456px from top )
- H1 : Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings , ( 6456px from top )